Reference 2019-163

REF:           2019-163

Subject:       Biosimilar biologic therapies

 

Request:

This is a freedom of information request relating to the use of the new biosimilar biologic therapies.

 

1. Does your trust use the following biosimilar biologic therapies, and if possible how many patients are currently being treated ?

Adalimumab [Hyrimoz]  No/Yes [if Yes number …..]

Adalimumab [Amgevita]  No/Yes [if Yes number …..]

Adalimumab [Imraldi]   No/Yes [if Yes number …..]

Adalimumab [Hulio]  No/Yes [if Yes number …..]

Etanercept [Benepali]  No/Yes [if Yes number …..]

Etanercept [Erelzi]  No/Yes [if Yes number …..]

Infliximab [Inflectra]  No/Yes [if Yes number …..]

Infliximab [Remsima]  No/Yes [if Yes number …..]

Infliximab [Flixabi]  No/Yes [if Yes number …..]

 

2. Within your rheumatology department;

a. how many patients in the year 2018 were treated with a biologic or JAK2

b. how many patients in the year 2018 were treated with a DMARD [for example azathioprine, ciclosporin, methotrexate, hydroxychloroquine, leflunomide, sulfasalazine or minocycline]

 

3. Within your dermatology department;

a. how many patients in the year 2018 were treated with a biologic or JAK2

b. how many patients in the year 2018 were treated with a DMARD [for example azathioprine, ciclosporin, methotrexate, hydroxychloroquine, leflunomide, sulfasalazine or minocycline]

 

4. Within your gastrenterology department;

a. how many patients in the year 2018 were treated with a biologic or JAK2

b. how many patients in the year 2018 were treated with a DMARD [for example azathioprine, ciclosporin, methotrexate, hydroxychloroquine, leflunomide, sulfasalazine or minocycline]

 

5. Does your trust record the DAS score electronically on the patient records? If so how many are DAS 5+   No/Yes [if Yes number …..]

 

 

Response:

Please find information attached.

2019-163 – FOI Request – Biosimilar biologic therapies [111 kb] PDF